Study details
Enrolling now
Anticholinergic Deprescription in Schizophrenia
Deepak K. Sarpal, M.D.
NCT IDNCT06562608ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
105
Study length
about 4.4 years
Ages
40–70
Locations
1 site in PA
About this study
Researchers are testing whether stopping unnecessary anticholinergic medications can improve quality of life, functioning, and thinking skills in people with schizophrenia. Participants will be randomly assigned to either continue taking their current medication or undergo a deprescribing process if deemed clinically appropriate. The trial will last for 1610 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Anticholinergic Deprescription
- 2.Take No Anticholinergic Deprescription
PhasePhase 4
Primary goalChange in scores on quality of life assessments
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low8%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Change in scores on quality of life assessments.
Body systems
Psychiatry / Mental Health